▎WuXi AppTec Content Team Report

Today (April 8), Arnatar Therapeutics, which is committed to the development of nucleic acid drugs,Arnatar Therapeutics Announces Completion of Series A Financing Round Exceeding 50 Million USDSequoia Capital, 3E Bioventures, Cowin Capital, Gaorong Capital, Lyfe Capital, New Alliance Capital, Yi Jing Capital, Legend Star, Harvest Capital, Chuanhua CapitalCompleted together.Arnatar Therapeutics Press Release Notes,The proceeds of this fundraising will be mainly used to accelerate the company's drugIn-depth layout of the product pipeline, rapid advancement of clinical trials, and the operational implementation of Chinese companies.Previously, Arnatar Therapeutics completed a nearly RMB 100 million seed round led exclusively by Apricot Capital in September 2022.Financing。

Arnatar was founded in 2022, by global nucleic acid drug fieldFounded by a team of scientists,BuiltBreakthrough InnovationNucleic acid drug platform, continuously exploring new mechanisms of nucleic acid-based drugs, covering multiple therapeutic areas.。

According to the introduction on Arnatar's official website, the company is leveraging innovative Antisense Technology and utilizingRNA Interference (RNAi) and Antisense Oligonucleotide (ASO) PlatformsRegulate the expression of target genes, thereby providingLiver, Extrahepatic Organ Diseases, and Common, Rare DiseasesProviding opportunities for treatment.

RNAi is a method of gene silencing mediated by double-stranded RNA.Some of these target specific genes in a sequence-dependent manner and suppress their expression, known as siRNA. As a new technological drug that has emerged in recent years, siRNA drugs boast advantages such as multiple druggable targets, potent efficacy, good safety, low dosing frequency, and broad therapeutic areas, making them one of the most promising frontier pharmaceutical fields globally.

ASOIs a single-stranded oligonucleotide molecule, after entering the cell, it binds to the target mRNA through sequence complementarity,Can lead to mRNA degradation, or alter mRNA splicing,Thereby achieving the effect of targeting the underlying mechanisms of diseases at the mRNA level and treating diseases.。